Company intelligence / Profile preview

Avista Public Acquisition

New York City, New York, United States

Ownership: Private
Development stage: Other

Overview

Avista Public Acquisition Corp. II was a special purpose acquisition company (SPAC) formed to acquire or merge with a healthcare-focused business. It completed its $230 million IPO in August 2021 and focused on effecting a business combination in the healthcare sector. In 2022, it completed a merger with OmniAb, Ligand Pharmaceuticals’ antibody discovery platform, resulting in OmniAb, Inc. becoming an independent publicly traded company and Avista Public Acquisition Corp. II ceasing to exist as a standalone entity. Avista Public Acquisition Corp. II had no operations, revenues, or clinical assets of its own.

Industry: Investors

Beyond the preview

Go deeper on Avista Public Acquisition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avista Public Acquisition.

Explore the full profile